ADL5945

ADL5945 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ADL5945, covering 2015-05-07 to 2015-06-08. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain [Phase 2]

See pricing